Have you ever dreamed of a future without Dutchtype CAA? We sure have. And the odds are finally in our favour! The Dutchtype CAA patient association, the Dutch CAA Foundation, researchers in Leiden (Netherlands), Boston (USA) and Perth (AUS), and the pharma companies Alnylam and Regeneron are working together towards a drug trial.

As drug development is never straightforward, there are no promises. But, we do need you to bring the possibility of a drug closer! By participating in the study TRACK DCAA in Perth, you will help us learn more about how DCAA develops in the brains of gene carriers. And that information is vital if we want to be part of a drug trial with a potential drug for Dutchtype CAA.

We understand what we are asking of you. Participation in TRACK DCAA is a direct confrontation with the disease, the hospital, scans… It also means you need to take time of work and for some of you, travelling up and down to Perth. Participation means making a huge effort. So why are we asking you to? Because if you don’t, there won’t be a drug trial in Australia. That means that you will not have access to a drug that potentially slows the disease down.

The time is now, as Alnylam is currently designing a drug trial with ALN-APP. That means that we have to jump on board while the opportunity is here. Right now we are working together with large pharma companies that have the potential, opportunity, capital and a specific potential therapy. It is now that we are working towards a drug trial in the Netherlands. And we very much want to bring it to Australia too. Want to know more about what it means to participate? Read more.